Description
CS10 is described as a fixed blend of cagrilintide 5 mg and semaglutide 5 mg. This combination is investigational and is not an FDA-approved finished drug product in the United States.
CS10 is described as a fixed blend of cagrilintide 5 mg and semaglutide 5 mg. This combination is investigational and is not an FDA-approved finished drug product in the United States.
CS10 is described as a fixed blend of cagrilintide 5 mg and semaglutide 5 mg. This combination is investigational and is not an FDA-approved finished drug product in the United States.
| Quantity | 10mg |
|---|
Reviews
There are no reviews yet.